The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients
- PMID: 16337931
- DOI: 10.1016/j.cellimm.2005.01.012
The CD160+ CD8high cytotoxic T cell subset correlates with response to HAART in HIV-1+ patients
Abstract
We investigated the circulating cytotoxic CD160+ CD8(high) subset in correlation to antiviral immunity and response to highly active antiretroviral therapy (HAART) in HIV+ subjects. The study included 45 treatment-naive patients receiving HAART for 18 months, retrospectively defined as good (n=29) and transient (n=16) responders. HIV-specific CD8 T lymphocyte levels were measured by IFNgamma production in response to p17 Gag, in the presence of immobilized anti-CD160 mAb. We report a significantly increased baseline level of CD160+ CD8(high) subset in good therapy responders. CD160+ CD8(high) subset correlates with CD4+ T cell count, immune activation, and viral load. CD160+ CD8(high) lymphocytes contain a high amount of Granzyme B and include virus-specific T lymphocytes in HIV-1+ subjects. Co-stimulation through CD160 molecules enhances IFNgamma production in response to p17 Gag. Therefore, the CD160+ CD8(high) subset may be useful for monitoring of virus-specific cellular immunity and predicting response to antiretroviral therapy in chronic HIV-1 infection.
Similar articles
-
Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART).J Immunol. 1999 Feb 1;162(3):1780-8. J Immunol. 1999. PMID: 9973442
-
Human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy maintain activated CD8+ T cell subsets as a strong adaptive immune response to cytomegalovirus.J Infect Dis. 2001 Aug 1;184(3):256-67. doi: 10.1086/322028. Epub 2001 Jul 10. J Infect Dis. 2001. PMID: 11443550
-
Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.Eur J Immunol. 2008 Jun;38(6):1548-58. doi: 10.1002/eji.200738054. Eur J Immunol. 2008. PMID: 18421792
-
Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection.Clin Sci (Lond). 1999 Dec;97(6):707-18. Clin Sci (Lond). 1999. PMID: 10585898 Review.
-
Effects of antiretroviral therapy on immune reconstitution.Antivir Ther. 1999;4 Suppl 3:3-6. Antivir Ther. 1999. PMID: 16021864 Review.
Cited by
-
Elevated Expression of CD160 and 2B4 Defines a Cytolytic HIV-Specific CD8+ T-Cell Population in Elite Controllers.J Infect Dis. 2015 Nov 1;212(9):1376-86. doi: 10.1093/infdis/jiv226. Epub 2015 Apr 15. J Infect Dis. 2015. PMID: 25883386 Free PMC article.
-
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.J Immunol. 2008 Jan 15;180(2):948-56. doi: 10.4049/jimmunol.180.2.948. J Immunol. 2008. PMID: 18178835 Free PMC article.
-
CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.PLoS One. 2013 Apr 4;8(4):e60391. doi: 10.1371/journal.pone.0060391. Print 2013. PLoS One. 2013. PMID: 23593209 Free PMC article.
-
CD160 and PD-1 co-expression on HIV-specific CD8 T cells defines a subset with advanced dysfunction.PLoS Pathog. 2012;8(8):e1002840. doi: 10.1371/journal.ppat.1002840. Epub 2012 Aug 16. PLoS Pathog. 2012. PMID: 22916009 Free PMC article. Clinical Trial.
-
CD160 Plays a Protective Role During Chronic Infection by Enhancing Both Functionalities and Proliferative Capacity of CD8+ T Cells.Front Immunol. 2020 Sep 11;11:2188. doi: 10.3389/fimmu.2020.02188. eCollection 2020. Front Immunol. 2020. PMID: 33072082 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
